LIVN
LivaNova PLC
Medical - Devices
Market Cap$3.88B
5Y Perf.+32.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LIVN vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
LIVN vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LIVN | DBVT |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $3.88B | $1712.35T |
| Revenue (TTM) | $1.43B | $0.00 |
| Net Income (TTM) | $107M | $-168M |
| Gross Margin | 67.5% | — |
| Operating Margin | 13.4% | — |
| Forward P/E | 16.8x | — |
| Total Debt | $473M | $22M |
| Cash & Equiv. | $636M | $194M |
LIVN vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LIVN
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| LivaNova PLC (LIVN) | 100 | 132.6 | +32.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LIVN vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIVN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LIVN
LivaNova PLC
The Growth Play
LIVN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 10.7%, EPS growth -483.6%, 3Y rev CAGR 10.8%
- 46.2% 10Y total return vs DBVT's -87.0%
- 10.7% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LIVN | 10.7% revenue growth vs DBVT's -100.0% |
| Quality / Margins | LIVN | 7.5% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs LIVN's 1.29, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs LIVN's +63.0% |
| Efficiency (ROA) | LIVN | 4.2% ROA vs DBVT's -89.0% |
LIVN vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
LIVN vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLIVNLAGGINGDBVT
DBVTDBV Technologies S.A.
0leads
LIVNLivaNova PLC
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LIVN1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LIVN5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
LIVN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LIVN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LIVN and DBVT operate at a comparable scale, with $1.4B and $0 in trailing revenue.
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $1.4B | $0 |
| EBITDAEarnings before interest/tax | $220M | -$112M |
| Net IncomeAfter-tax profit | $107M | -$168M |
| Free Cash FlowCash after capex | $161M | -$151M |
| Gross MarginGross profit ÷ Revenue | +67.5% | — |
| Operating MarginEBIT ÷ Revenue | +13.4% | — |
| Net MarginNet income ÷ Revenue | +7.5% | — |
| FCF MarginFCF ÷ Revenue | +11.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +106.7% | +91.5% |
LIVN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LIVN and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $3.9B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -15.94x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.84x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 15.40x | — |
| Price / SalesMarket cap ÷ Revenue | 2.79x | — |
| Price / BookPrice ÷ Book value/share | 3.22x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 22.40x | — |
Evenly matched — LIVN and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
LIVN leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
LIVN delivers a 9.1% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to LIVN's 0.39x. On the Piotroski fundamental quality scale (0–9), LIVN scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +9.1% | -130.2% |
| ROA (TTM)Return on assets | +4.2% | -89.0% |
| ROICReturn on invested capital | +11.5% | — |
| ROCEReturn on capital employed | +10.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.39x | 0.13x |
| Net DebtTotal debt minus cash | -$162M | -$172M |
| Cash & Equiv.Liquid assets | $636M | $194M |
| Total DebtShort + long-term debt | $473M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 3.98x | -189.82x |
LIVN leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
LIVN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIVN five years ago would be worth $8,546 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs LIVN's +63.0%. The 3-year compound annual growth rate (CAGR) favors LIVN at 14.6% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +17.0% | +4.9% |
| 1-Year ReturnPast 12 months | +63.0% | +110.4% |
| 3-Year ReturnCumulative with dividends | +50.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | -14.5% | -69.1% |
| 10-Year ReturnCumulative with dividends | +46.2% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +14.6% | +6.2% |
LIVN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LIVN and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than LIVN's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.26x |
| 52-Week HighHighest price in past year | $71.92 | $26.18 |
| 52-Week LowLowest price in past year | $39.36 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +98.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 808K | 252K |
Evenly matched — LIVN and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LIVN as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 7.0% for LIVN (target: $76).
| Metric | LIVNLivaNova PLC | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $75.88 | $46.33 |
| # AnalystsCovering analysts | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LIVN leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallLivaNova PLC (LIVN)Leads 3 of 6 categories
Loading custom metrics...
LIVN vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is LIVN or DBVT a better buy right now?
Analysts rate LivaNova PLC (LIVN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LIVN or DBVT?
Over the past 5 years, LivaNova PLC (LIVN) delivered a total return of -14.
5%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: LIVN returned +46. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LIVN or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus LivaNova PLC's 1. 29β — meaning LIVN is approximately 3% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 39% for LivaNova PLC — giving it more financial flexibility in a downturn.
04Which is growing faster — LIVN or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -483. 6% for LivaNova PLC. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LIVN or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -17. 5% for LivaNova PLC — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — LIVN leads at 67. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is LIVN or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — LIVN or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is LIVN or DBVT better for a retirement portfolio?
For long-horizon retirement investors, LivaNova PLC (LIVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
29)). Both have compounded well over 10 years (LIVN: +46. 2%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between LIVN and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.